Cargando…

Drugs with a negative impact on cognitive functions (Part 2): drug classes to consider while prescribing in CKD patients

There is growing evidence that chronic kidney disease (CKD) is an independent risk factor for cognitive impairment, especially due to vascular damage, blood–brain barrier disruption and uremic toxins. Given the presence of multiple comorbidities, the medication regimen of CKD patients often becomes...

Descripción completa

Detalles Bibliográficos
Autores principales: Hafez, Gaye, Malyszko, Jolanta, Golenia, Aleksandra, Klimkowicz-Mrowiec, Aleksandra, Ferreira, Ana Carina, Arıcı, Mustafa, Bruchfeld, Annette, Nitsch, Dorothea, Massy, Ziad A, Pépin, Marion, Capasso, Giovambattista, Mani, Laila-Yasmin, Liabeuf, Sophie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10689198/
https://www.ncbi.nlm.nih.gov/pubmed/38046029
http://dx.doi.org/10.1093/ckj/sfad239
_version_ 1785152321072660480
author Hafez, Gaye
Malyszko, Jolanta
Golenia, Aleksandra
Klimkowicz-Mrowiec, Aleksandra
Ferreira, Ana Carina
Arıcı, Mustafa
Bruchfeld, Annette
Nitsch, Dorothea
Massy, Ziad A
Pépin, Marion
Capasso, Giovambattista
Mani, Laila-Yasmin
Liabeuf, Sophie
author_facet Hafez, Gaye
Malyszko, Jolanta
Golenia, Aleksandra
Klimkowicz-Mrowiec, Aleksandra
Ferreira, Ana Carina
Arıcı, Mustafa
Bruchfeld, Annette
Nitsch, Dorothea
Massy, Ziad A
Pépin, Marion
Capasso, Giovambattista
Mani, Laila-Yasmin
Liabeuf, Sophie
author_sort Hafez, Gaye
collection PubMed
description There is growing evidence that chronic kidney disease (CKD) is an independent risk factor for cognitive impairment, especially due to vascular damage, blood–brain barrier disruption and uremic toxins. Given the presence of multiple comorbidities, the medication regimen of CKD patients often becomes very complex. Several medications such as psychotropic agents, drugs with anticholinergic properties, GABAergic drugs, opioids, corticosteroids, antibiotics and others have been linked to negative effects on cognition. These drugs are frequently included in the treatment regimen of CKD patients. The first review of this series described how CKD could represent a risk factor for adverse drug reactions affecting the central nervous system. This second review will describe some of the most common medications associated with cognitive impairment (in the general population and in CKD) and describe their effects.
format Online
Article
Text
id pubmed-10689198
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-106891982023-12-02 Drugs with a negative impact on cognitive functions (Part 2): drug classes to consider while prescribing in CKD patients Hafez, Gaye Malyszko, Jolanta Golenia, Aleksandra Klimkowicz-Mrowiec, Aleksandra Ferreira, Ana Carina Arıcı, Mustafa Bruchfeld, Annette Nitsch, Dorothea Massy, Ziad A Pépin, Marion Capasso, Giovambattista Mani, Laila-Yasmin Liabeuf, Sophie Clin Kidney J CKJ Review There is growing evidence that chronic kidney disease (CKD) is an independent risk factor for cognitive impairment, especially due to vascular damage, blood–brain barrier disruption and uremic toxins. Given the presence of multiple comorbidities, the medication regimen of CKD patients often becomes very complex. Several medications such as psychotropic agents, drugs with anticholinergic properties, GABAergic drugs, opioids, corticosteroids, antibiotics and others have been linked to negative effects on cognition. These drugs are frequently included in the treatment regimen of CKD patients. The first review of this series described how CKD could represent a risk factor for adverse drug reactions affecting the central nervous system. This second review will describe some of the most common medications associated with cognitive impairment (in the general population and in CKD) and describe their effects. Oxford University Press 2023-09-18 /pmc/articles/PMC10689198/ /pubmed/38046029 http://dx.doi.org/10.1093/ckj/sfad239 Text en © The Author(s) 2023. Published by Oxford University Press on behalf of the ERA. https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (https://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle CKJ Review
Hafez, Gaye
Malyszko, Jolanta
Golenia, Aleksandra
Klimkowicz-Mrowiec, Aleksandra
Ferreira, Ana Carina
Arıcı, Mustafa
Bruchfeld, Annette
Nitsch, Dorothea
Massy, Ziad A
Pépin, Marion
Capasso, Giovambattista
Mani, Laila-Yasmin
Liabeuf, Sophie
Drugs with a negative impact on cognitive functions (Part 2): drug classes to consider while prescribing in CKD patients
title Drugs with a negative impact on cognitive functions (Part 2): drug classes to consider while prescribing in CKD patients
title_full Drugs with a negative impact on cognitive functions (Part 2): drug classes to consider while prescribing in CKD patients
title_fullStr Drugs with a negative impact on cognitive functions (Part 2): drug classes to consider while prescribing in CKD patients
title_full_unstemmed Drugs with a negative impact on cognitive functions (Part 2): drug classes to consider while prescribing in CKD patients
title_short Drugs with a negative impact on cognitive functions (Part 2): drug classes to consider while prescribing in CKD patients
title_sort drugs with a negative impact on cognitive functions (part 2): drug classes to consider while prescribing in ckd patients
topic CKJ Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10689198/
https://www.ncbi.nlm.nih.gov/pubmed/38046029
http://dx.doi.org/10.1093/ckj/sfad239
work_keys_str_mv AT hafezgaye drugswithanegativeimpactoncognitivefunctionspart2drugclassestoconsiderwhileprescribinginckdpatients
AT malyszkojolanta drugswithanegativeimpactoncognitivefunctionspart2drugclassestoconsiderwhileprescribinginckdpatients
AT goleniaaleksandra drugswithanegativeimpactoncognitivefunctionspart2drugclassestoconsiderwhileprescribinginckdpatients
AT klimkowiczmrowiecaleksandra drugswithanegativeimpactoncognitivefunctionspart2drugclassestoconsiderwhileprescribinginckdpatients
AT ferreiraanacarina drugswithanegativeimpactoncognitivefunctionspart2drugclassestoconsiderwhileprescribinginckdpatients
AT arıcımustafa drugswithanegativeimpactoncognitivefunctionspart2drugclassestoconsiderwhileprescribinginckdpatients
AT bruchfeldannette drugswithanegativeimpactoncognitivefunctionspart2drugclassestoconsiderwhileprescribinginckdpatients
AT nitschdorothea drugswithanegativeimpactoncognitivefunctionspart2drugclassestoconsiderwhileprescribinginckdpatients
AT massyziada drugswithanegativeimpactoncognitivefunctionspart2drugclassestoconsiderwhileprescribinginckdpatients
AT pepinmarion drugswithanegativeimpactoncognitivefunctionspart2drugclassestoconsiderwhileprescribinginckdpatients
AT capassogiovambattista drugswithanegativeimpactoncognitivefunctionspart2drugclassestoconsiderwhileprescribinginckdpatients
AT manilailayasmin drugswithanegativeimpactoncognitivefunctionspart2drugclassestoconsiderwhileprescribinginckdpatients
AT liabeufsophie drugswithanegativeimpactoncognitivefunctionspart2drugclassestoconsiderwhileprescribinginckdpatients
AT drugswithanegativeimpactoncognitivefunctionspart2drugclassestoconsiderwhileprescribinginckdpatients